Business Wire

Mainstay Medical Announces Regulatory Approval from Australian Therapeutic Goods Administration (TGA) for ReActiv8

DUBLIN--(BUSINESS WIRE)--Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Growth operated by Euronext Dublin (MSTY.IE), today ...
Business Wire

Mainstay Medical Provides Company Update and Reports 2019 Full Year Financial Results

DUBLIN--(BUSINESS WIRE)--Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Growth of Euronext Dublin: MSTY.IE), a medical device ...

'Remote control' implant gives Newcastle woman her life back after years in 'unbearable pain'

Sam Naylor said that the ReActiv8 back implant has given her hope that she can live a life unburdened by chronic pain ...
Monthly Prescribing Reference

Implantable Neurostimulation Device Cleared for Chronic Low Back Pain

The Food and Drug Administration (FDA) has approved ReActiv8® (Mainstay Medical), an implantable neurostimulation system, for the treatment of intractable chronic low back pain. Specifically, the ...
BioWorld

FDA gives green light to Mainstay Medical’s Reactiv8 device

Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...
Geelong Advertiser

Implantable device offers hope to chronic back pain sufferers

After being surgically implanted, using it for just 30 minutes in the morning and again in the evening is reported to have a dramatic effect on back pain. The device, called ReActiv8, has been ...